Market Research Reports and Industry Reports

Kalvista Pharmaceuticals Inc (KALV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc is a pharmaceutical company that develops and markets biomaterial based therapies and medicals for the treatment of osteoarthritis. The companys products include hydros and hydros TA, which are used to treat knee osteoarthritis. Its hydros is a viscosupplementation therapy. Kalvistas hydros TA is a combination of hyaluronan and corticosteroid therapies. Its products are made from chemically engineered polymers of hyaluronic acid. The company develops products to treat the pain associated with osteoarthritis, a joint disorder including the degradation of the IA cartilage, joint lining, ligaments and, ultimately, and underlying bone. Kalvista is headquartered in Cambridge, Massachusetts, the US.

Kalvista Pharmaceuticals Inc (KALV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

3
List of Tables 4
List of Figures 4
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kalvista Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kalvista Acquires Plasma Kallikrein Inhibitors from Vantia Therapeutics 11
Venture Financing 12
KalVista Pharma Raises USD33 Million in Series B Financing 12
Carbylan Therapeutics Raises USD4 Million in Venture Financing 13
Carbylan Biosurgery Raises US$6 Million In Venture Financing 14
KalVista Pharma Secures US$13.2 Million In Series A Financing 15
Partnerships 16
KalVista Pharma Enters into Agreement with Merck 16
KalVista Pharma Enters Into Research Agreement With JDRF 17
Licensing Agreements 18
Carbylan BioSurgery Enters Into Licensing Agreement With Shanghai Jingfeng pharma For Hydros-TA Technology 18
Equity Offering 19
KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 19
KalVista Pharma Plans to Raise up to USD6 Million in Public Offering of Shares 20
Carbylan Therapeutics Raises USD74.75 Million in IPO 21
Acquisition 22
Carbylan Therapeutics Acquires KalVista Pharma 22
Kalvista Pharmaceuticals Inc - Key Competitors 24
Kalvista Pharmaceuticals Inc - Key Employees 25
Kalvista Pharmaceuticals Inc - Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Mar 16, 2017: KalVista Pharmaceuticals Reports Fiscal Third Quarter Results 27
Corporate Communications 28
Mar 09, 2017: KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical 28
Product News 29
05/19/2016: KalVista Pharmaceuticals to Support Global Conference Focused on Hereditary Angioedema 29
Clinical Trials 30
Feb 01, 2016: Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List Of Tables

List of Tables
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kalvista Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Kalvista Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 9
Kalvista Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kalvista Acquires Plasma Kallikrein Inhibitors from Vantia Therapeutics 11
KalVista Pharma Raises USD33 Million in Series B Financing 12
Carbylan Therapeutics Raises USD4 Million in Venture Financing 13
Carbylan Biosurgery Raises US$6 Million In Venture Financing 14
KalVista Pharma Secures US$13.2 Million In Series A Financing 15
KalVista Pharma Enters into Agreement with Merck 16
KalVista Pharma Enters Into Research Agreement With JDRF 17
Carbylan BioSurgery Enters Into Licensing Agreement With Shanghai Jingfeng pharma For Hydros-TA Technology 18
KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 19
KalVista Pharma Plans to Raise up to USD6 Million in Public Offering of Shares 20
Carbylan Therapeutics Raises USD74.75 Million in IPO 21
Carbylan Therapeutics Acquires KalVista Pharma 22
Kalvista Pharmaceuticals Inc, Key Competitors 24
Kalvista Pharmaceuticals Inc, Key Employees 25
Kalvista Pharmaceuticals Inc, Subsidiaries 26

Kalvista Pharmaceuticals Inc (CBYL) - Financial and Strategic SWOT Analysis Review

Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc is a pharmaceutical company that develops and markets biomaterial based therapies and medicals for the treatment of osteoarthritis. The companys products include

USD 300View Report

Kalvista Pharmaceuticals Inc (KALV) - Medical Equipment - Deals and Alliances Profile

Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc is a pharmaceutical company that develops and markets biomaterial based therapies and medicals for the treatment of osteoarthritis. The companys products include

USD 250View Report

Sonoma Pharmaceuticals Inc (SNOA) - Medical Equipment - Deals and Alliances Profile

Sonoma Pharmaceuticals Inc (Sonoma), formerly Oculus Innovative Sciences is a pharmaceutical company that develops, manufactures and markets prescription and non-prescription products for the treatment of dermatological conditions and advanced tissue

USD 250View Report

Karuna Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Karuna Pharmaceuticals Inc (Karuna Pharmaceuticals), a subsidiary of Puretech Health plc is a clinical-stage company that develops muscarinic receptors for the treatment of CNS disorders. The companys products include KarXT.

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Oct 2017
No. of Pages :31
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube